Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc. (NASDAQ: VERV) in a deal valued at up to $1.3 billion, according to the Financial Times. This move underscores Eli Lilly’s aggressive expansion into genetic medicine as it seeks to boost its pipeline of experimental drugs.
Verve Therapeutics’ stock skyrocketed nearly 73% in after-hours trading, reaching $10.76, following the news. The proposed deal would include a $1 billion upfront payment and an additional $300 million tied to performance-based milestones. The acquisition price values Verve at approximately double its market capitalization of just over $500 million as of Monday's close.
The Boston-based Verve specializes in in vivo gene editing treatments aimed at cardiovascular disease. Eli Lilly’s interest lies in leveraging Verve’s proprietary CRISPR-based technology to diversify and enhance its R&D capabilities.
This potential acquisition adds to Eli Lilly’s recent M&A streak. Earlier in 2025, the pharmaceutical giant acquired Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion, signaling a clear strategy to invest in innovative biotech platforms.
Despite broader industry challenges, Eli Lilly continues to outperform competitors, driven by strong sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. By acquiring Verve, Lilly aims to strengthen its long-term competitiveness in the fast-evolving field of gene therapies.
Investors are watching closely as the deal, if finalized, could mark a major turning point for both companies and the broader gene editing space. Eli Lilly’s push into advanced therapeutics reaffirms its leadership in shaping the future of precision medicine and biopharmaceutical innovation.
